Subcutaneous formulation comprising the anti-cd20 Antibody rituximab obinutuzumab: ocrelizumab, or, and the Enzyme hyaluronidase: rhuph20

摘要

Referring to a Pharmaceutical formulation comprising: (a) 50 - 350 mg / ml anti CD 20 Antibody (rituximab); (b) approx. 1 - 100 mm of a buffering Agent to maintain the pH 5.5 + 2.0 as histidine; (c) approx. 1 - 500 mm of a Stabilizer or a mixture of two or more stabilizers such as Alpha, Alpha trehalosadihidratada, sucrose; (d) approx.0.01 - 0.1% of a nonionic Surfactant selected from Polysorbate 20, Polysorbate 80, Polyethylene polypropylene Copolymer; and (e) approx. Of 1.000-16.000 U / ml of a hyaluronidase Enzyme rhuph20, with Preference 2.000-12.000 U / ml subcutaneous Administration. This composition is useful in the treatment of cancer